Lv3
300 积分 2023-06-16 加入
Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer
18天前
已完结
Structure-Based Discovery of HS34: A Highly Selective and Orally Bioavailable CDK9 Inhibitor for Triple-Negative Breast Cancer
18天前
已完结
Total Synthesis of Cyclotripeptidic Natural Products Anacine, Aurantiomide C, Polonimides A and C, and Verrucine F
1个月前
已完结
Molecular recognition, fluorescence sensing, and biological assay of phosphate anion derivatives using artificial Zn(ii)–Dpa complexes
3个月前
已完结
Recent Developments in Cyclin-Dependent Kinase (CDK) PROTAC in Cancer Therapy
3个月前
已完结
Inhibitors and PROTACs of CDK2: challenges and opportunities
3个月前
已完结
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
3个月前
已完结
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
4个月前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
5个月前
已完结
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor
6个月前
已完结
皖公网安备34019202002308
